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Abstract
Purpose It has been established that the infection with SARS-CoV-2 may cause an impairment of chemosensory function. 
However, there is little data on the long-term effects of SARS-CoV-2 infection on chemosensory function.
Methods Twenty three SARS-CoV-2-positive patients diagnosed in spring 2020 with subjective hyposmia (out of 57 positive 
patients, 40.3%) were compared to SARS-CoV-2-positive patients without hyposmia (n = 19) and SARS-CoV-2-negative 
patients (n = 14). Chemosensory function was assessed by the Brief Smell Identification Test (BSIT), Taste Strips (TS), 
Visual Analogue Scales (VAS), and the SNOT-22. The initial cohort with hyposmia were also examined at 8 weeks and 
6 months after initial examination.
Results There were no differences between the SARS-CoV-2-positive cohort without hyposmia and negative controls in terms 
of BSIT (8.5 ± 2.6 vs. 10.2 ± 1.8), TS (3.4 ± 0.6 vs. 3.9 ± 0.3) or VAS (2.1 ± 1.3 vs. 1.1 ± 0.5); yet the SNOT-22 was signifi-
cantly elevated (27.7 ± 11.2 vs. 16.4 ± 10.8). The SARS-CoV-2-positive group with hyposmia performed significantly poorer 
in BSIT (4.0 ± 1.7 vs. 8.5 ± 2.6/10.2 ± 1.8), TS (2.6 ± 1.3 vs. 3.4 ± 0.6/3.9 ± 0.3), and VAS (7.9 ± 2.2 vs. 2.1 ± 1.3/1.1 ± 0.5) 
compared to both control groups. At week 8 and month 6 control, six and five patients, respectively, still suffered from sub-
jectively and objectively impaired chemosensory function. The other patients had recovered in both respects.
Conclusion SARS-CoV-2 patients with subjectively impaired chemosensory function regularly perform poorly in objective 
measurements. About 70% of patients suffering from olfactory dysfunction in SARS-CoV-2 quickly recover—the rest still 
suffers from considerable impairment 6 months after infection.
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Abbreviations
BSIT  Brief smell identification test
COVID-19  Coronavirus disease 2019
SNOT-22  Sino-nasal outcome test (22 Items)
TS  Taste strips
VAS  Visual Analogue Scale
Introduction
The coronavirus SARS-CoV-2 first rose to global attention 
in December 2019, when it was regularly found to cause 
severe pneumonia [1]. The symptom complex was later 
named COVID-19. Due to its high contagiosity it quickly 
spread to Europe and the Americas and caused an unprec-
edented social and economic disruption with its (relatively) 
high lethality. The WHO considered COVID-19 to be a “a 
public health emergency of international concern”, on the 
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30th of January and even updated it to be a “pandemic” as 
of 11th of March, 2020.
Initial research on the virus focused strongly on its ori-
gin, genetic properties, individual risk factors, and poten-
tial treatments. This was ratiocinative, given the pressing 
matters at hand. However, as time passed and coping with 
SARS-CoV-2 gradually became routine, starting in April 
reports arose that an impaired sense of smell and/or taste 
was a common symptom of infection with SARS-CoV-2 
[2–4]. Subsequent quantitative data on the matter showed 
that a considerable amount of patients that tested positive 
for SARS-CoV-2 actually suffered from impaired sense of 
smell [5].
However, olfactory dysfunction has only been inves-
tigated in a minor extent—compared to other aspects of 
COVID-19. As it has been suggested that a great majority 
of patients suffering from chemosensory dysfunction even-
tually resolve symptoms within a short period of time, [6, 
7] there is—to this day—little quantitative data available on 
long-term effects of SARS-CoV-2 infection on smell and 
taste function. This is particularly important as especially 
long-term chemosensory dysfunction is associated with a 
number of severe psychosocial disorders as decreased sexual 
attraction [8] and increased risk for depression [9, 10].
As there is little data available on the long-term effects 
of infection with SARS-CoV-2 on individual perception, 
we conducted a retrospective chart review of the long-term 
course of chemosensory dysfunction after SARS-CoV-2 
infection.
Materials and methods
The study at hand was registered with the ethics commit-
tee of the Ludwig-Maximilians University (Munich, Fed-
eral Republic of Germany) under the file number 20-253. 
Patients in this study that had tested positive for SARS-
CoV-2 were also included in the prospective CORKUM 
(CORona virus disease atthe Klinikum der Universtität 
München) study under the file no. 20-245 The study was 
conducted in compliance with the Declaration of Helsinki 
from 2000.
All patients that had been registered with the ICD-10 
code U07.1 (COVID-19) and had tested positive for SARS-
CoV-2 by polymerase chain reaction in the spring of 2020 
were screened for this study. Patients that had been tested 
positive for SARS-CoV-2 during spring 2020 were divided 
into two groups—patients that stated to suffer from sub-
jective impairment of chemosensory function (smell and/
or taste) and those that did not. Patients were asked regu-
larly whether they had been experiencing impaired sense of 
smell and/or taste as part of the routine work-up during their 
inpatient stay. A third group of patients that were sched-
uled for ear surgery and had no prior history of conditions 
of the nose or paranasal sinuses was used as a control, as 
these patients routinely underwent SARS-CoV-2 testing pre-
operatively (Fig. 1).
(Electronic) patient files were then used to obtain infor-
mation on the patients individual and COVID-19 specific 
characteristics. Individual characteristics included age, gen-
der, general diseases, medication that was taken on a regular 
base. COVID-19 characteristics included the way of infec-
tion as well as the date, the time of onset of symptoms and 
symptoms other than hyposmia that have been reported to 
occur in COVID-19, such as odynophagia, fever, tiredness, 
dry cough, sneezing, myalgia, nasal obstruction, nausea, 
diarrhea and hemoptysis.
Chemosensory dysfunction was measured by the “Brief 
Smell Identification Test” (BSIT). The BSIT is an abbrevi-
ated version of the University of Pennsylvania Smell Identi-
fication Test (UPSIT), a supra-threshold odor identification 
test that has been established as a reliable measurement of 
smell function [11]. The BSIT (purchased from Sense Trad-
ing, Groningen, The Netherlands) contains 12 odors and was 
administered as recommended by the provider: Patients were 
handed the booklet containing the 12 odors. Upon scratch-
ing each of the 12 contact fields with a pencil, patients were 
asked to pick one out of four answers as to what smell they 
have been exposed to. It has been shown that BSIT values 
strongly correlate with the UPSIT [12]. As recommended 
in recent literature, values equal to or smaller than nine out 
of twelve were considered to be a indicative of impaired 
smell (hyposmia), [12] values equal to or smaller than four 
were considered to be indicative of anosmia. For the taste 

















Duration of subjective hyposmia [days]
Fig. 1  Duration of subjectively impaired chemosensory func-
tion and the last available objective measurements of smell (BSIT). 
Blue = Chemosensory impairment had resolved at the last examina-
tion, yellow = chemosensory impairment was still present at the last 
examination
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extensively were used [13]. For each taste, only the highest 
concentrations were used so as to determine whether the 
patient was able to taste each quality or not. The SNOT-22 
was filled out by the patients digitally via a QR-code as pro-
vided by the software ENT-Statistics (Innoforce Est, Rugell, 
Principality of Liechtenstein). If the patient had no handheld 
electronic device capable of reading a QR-code, the SNOT-
22 was completed verbally with an ENT-specialist. Moreo-
ver, patients were asked to grade the amount of chemosen-
sory dysfunction on a visual anaolgue scale ranging from 1 
(no impairment at all) to 10 (highest possible impairment).
Patients that had stated to suffer from impaired chem-
osensory function were subsequently examined at scheduled 
follow-up visits at sister departments or were asked to par-
ticipate in follow-up examinations either in an outpatient 
setting or by mail. Follow-up examinations were performed 
8 weeks after initial examination and after 6 months. During 
follow-ups, patients were asked if they still suffered from 
subjective impairment of chemosensory function, to grade 
the impairment on a visual analogue scale and were asked 
to complete the B-SIT and taste strip examinations as well 
as the SNOT-22.
Statistical analysis was carried out using RStudio for Mac 
(Version 1.2.1335, RStudio Inc., Boston, MA, United States 
of America). A p value of smaller than 0.05 was considered 
to be significant.
Results
Initially, 57 patients that tested positive during April 2020 
for SARS-CoV-2 by polymerase chain reaction and had 
been hospitalized were screened for this study. Average 
age was 64.9 ± 14.7 years. 42 were male and 15 female. 
Out of these 23 patients reported to experience impaired 
chemosensory function (40.3%). Those patients made up 
the positive cohort that suffered subjective hyposmia.
Out of these 23 patients, 17 (77.3%) were male and six 
female. Average age was 59.0 ± 16.6 years. Average score 
on the SNOT-22 was 24.2 ± 9.8. Subjective chemosensory 
impairment (VAS) was graded on average with 7.9 ± 2.2. 
The B-SIT showed an average of 4.0 ± 1.7 points (out 
of 12 points). 16 patients suffered from anosmia and six 
patients suffered from hyposmia. In terms of taste strips, 
patients scored on average 2.6 ± 1.3 points (out of 4). 10 
Table 1  Comparison of characteristics between baseline groups
Values are given as mean ± standard deviation. Bold indicates p < 0.05, # = Fisher’s exact test, † = Wilcoxon signed rank test
SARS-CoV-2-positive with Hyposmia 
(n = 23)
SARS-CoV-2-positive without Hypos-




Age (years) 59.0 ± 16.6 68.0 ± 17.3 61.7 ± 18.0
Gender (male) 17 (77.3%) 15 (78.9%) 10 (71.4%)
SNOT-22 24.2 ± 9.8 27.7 ± 11.2 16.4 ± 10.8
VAS 7.9 ± 2.2 2.1 ± 1.3 1.1 ± 0.5
B-SIT 4.0 ± 1.7 8.5 ± 2.6 10.2 ± 1.8
Normosmia 0 (0.0%) 9 (47.3%) 10 (71.4%)
Hyposmia 6 (27.3%) 8 (42.1%) 4 (28.6%)
Anosmia 16 (72.7%) 2 (10.5%) 0 (0.0%)
Taste strips 2.6 ± 1.3 3.4 ± 0.6 3.9 ± 0.3
Normogeusia 10 (45.5%) 16 (84.2%) 14 (100.0%)
Hypogeusia 11 (50.0%) 3 (15.8%) 0 (0.0%)
Ageusia 1 (4.5%) 0 (0.0%) 0 (0.0%)
Mortality 0 (0.0%) 4 (21.1%) 0 (0.0%)
Statistics (p values)
SARS + H + vs. SARS + H − SARS + H + vs. SARS − SARS + H – vs. 
SARS −
SNOT-22 0.383# < 0.001# 0.008#
VAS < 0.001# < 0.001# < 0.001#
BSIT (absolute values) 0.002# < 0.001# 0.5936#
BSIT (interpretation) < 0.001† < 0.001† 0.4537†
Taste strips (absolute values) 0.067# 0.014# 0.2444#
Taste strips (interpretation) 0.013† < 0.001† 0.2443†
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patients showed normogeusia, 11 showed hypogeusia and 
one patient showed ageusia as per the previously defined 
criteria. As of the last follow-up, there was no mortality 
amongst this group of patients (Table 1).
Compared to this, controls that were tested positive 
for SARS-CoV-2 but that did not suffer from subjective 
impairment of chemosensory function consisted of 19 
patients. These were recruited after the initial cohort had 
been recruited. Out of these, 15 (78.9%) were male and four 
(21.1%) were female. Average age was 68.0 ± 17.3 years. On 
average, patients scored 27.7 ± 11.2 points on the SNOT-22 
and reported chemosensory function to be 2.1 ± 1.1 on a 
visual analogue scale. There was no statistically significant 
difference between these patients and the positive patients 
with Hyposmia, but a significant difference between those 
patients and the negative controls. Patients scored on average 
8.5 (out of 12) ± 2.6 on the BSIT. Out of those, nine (47.3%) 
patients showed normosmia, eight patients (42.1%) showed 
hyposmia and two patients (10.5%) showed anosmia. This 
was significantly different compared to patients positive for 
SARS-CoV-2 with hyposmia but not compared to negative 
controls. In terms of taste, patients scored 3.4 ± 0.6, result-
ing in 16 patients with normogeusia (84.2%), three patients 
with hypogeusia (15.8%) and no patients with ageusia. This 
was only significantly different from SARS-CoV-2-positive 
patients with hyposmia in respect to the interpretation of the 
taste strips. Four of the 19 patients had died in the course of 
the disease (Table 1).
The control group that had tested negative for SARS-
CoV-2 was on average 61.7 ± 18.0-years-old. Out of those 
patients, ten (71.4%) were male. Participants scored on the 
SNOT 10 on average 16.4 ± 10.8 points. In terms of the 
individual analogue scale, patients scored 1.1 ± 0.5 points. 
Patients scored on average 10.2 ± 1.8 odors on the BSIT, 
resulting in ten (71.4%) patients with normosmia, four 
(28.6%) with hyposmia and no patients with anosmia. In 
terms of objective taste, all patients showed normogeusia 
(100.0%).
In brief, both groups that had tested positive for SARS-
CoV-2 were comparable in terms of comorbidities. In terms 
of symptoms, a sore throat, coughing and cephalgia was 
more common in the group that suffered from subjectively 
impaired chemosensory function (Table 2).
At the 8-week follow-up, twenty patients reported 
back. Out of these, six (30.0%) still claimed to suffer from 
impaired chemosensory function and 14 reported that 
impairment had resolved. The patients in which subjective 
hyposmia had resolved suffered from hyposmia for an aver-
age of 18.5 ± 8.4 days (7–30 days). Average scores on the 
SNOT-22 were 17.6 ± 7.6 points, on the VAS were 3.8 ± 2.6 
points, on the B-SIT 9.0 ± 3.1 points and 3.6 ± 0.8 points 
for the taste strips. Subsequently, 11 patients showed nor-
mosmia and eight showed hyposmia. 18 patients showed 
normogeusia and two hypogeusie. The respective values for 
the individual groups that showed persistent impairment of 
chemosensory function and those that did not can be found 
in Table 3.
At the 6-month follow-up, 17 patients reported back. 
Out of those, five (29.4%) patients stated to still suffer 
from subjective impairment of chemosensory function. 
Table 2  Comparison of symptoms and comorbidities between SARS-CoV-2 positive groups with and without Hyposmia
Bold writing indicates p < 0.05 by Fisher’s exact test
SARS-CoV-2-positive with 
Hyposmia (n = 23)
SARS-CoV-2-positive without 
Hyposmia (n = 19)
Odds ratio p
Comorbidities
 Immunosuppression 3 (13.0%) 4 (21.1%) 0.570 [0.039–5.074] 0.682
 Pulmonary diseases 2 (8.7%) 3 (15.8%) 0.516 [0.132–2.748] 0.516
 Arterial hypertension 13 (56.5%) 9 (47.3%) 1.432 [0.362–5.807] 0.757
 Malignoma 1 (4.3%) 5 (26.3%) 0.133 [0.002–1.370] 0.075
 Pollinosis 1 (4.3%) 1 (5.3%) 0.822 [0.009–67.719] 1.000
 History of nicotin abuse 3 (13.0%) 6 (31.6%) 0.334 [0.046–1.901] 0.257
Symptoms
 Sore throat 6 (26.1%) 0 (0.0%) ∞ [1.104–∞] 0.024
 Fever 20 (87.0%) 15 (78.9%) 1.753 [0.254–13.820] 0.682
 Tiredness 18 (78.3%) 10 (52.6%) 3.145 [0.711–15.631] 0.107
 Cough 20 (87.0%) 9 (47.4%) 7.020 [1.377–49.542] 0.008
 Myalgia 10 (43.5%) 3 (15.8%) 3.966 [0.795–27.147] 0.093
 Cephalgia 10 (43.5%) 1 (5.3%) 13.082 [1.528–631.146] 0.006
 Diarrhea 4 (17.4%) 0 (0.0%) ∞ [0.573–∞] 0.193
 Emesis 2 (8.7%) 0 (0.0%) ∞ [0.156–∞] 0.493
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Patients scored on average 20.3 ± 7.7 points on the SNOT-
22. Impairment of chemosensory function was graded on 
average with 3.8 ± 2.7 points on the VAS. Patients scored 
on average 9.4 ± 2.6 out of twelve odors in the B-SIT. 10 
patients showed normosmia, six patients still showed hypos-
mia and one patient showed persistent anosmia. In the taste 
strip examination, average score was 3.7 ± 0.5. All patients 
showed normogeusia. Individual values for patients that still 
claim to experience impaired chemosensory function can be 
found in Table 3.
A survival analysis with a cox proportional hazards mod-
els showed no influence of either the SNOT-22 (p = 0.7), the 
VAS (p = 0.3) or the B-SIT (p = 0.8) on the persistence of 
subjective chemosensory dysfunction.
Discussion
It has been established—albeit relatively late during this 
pandemic—that infection with SARS-CoV-2 may cause 
chemosensory dysfunction [5, 6]. There has been a large 
meta-analysis by Hannum and colleagues that reported the 
prevalence of chemosensory dysfunction in SARS-CoV-2 
infection to be as high as 77% (95% confidence interval 
61.4–89.2%) [14]. Taking into account all patients that had 
tested positive for SARS-CoV-2 in the study at hand, we 
found that 78% of these showed impaired chemosensory 
function, which is in line with the aforementioned study and 
speaks for the validity of the cohort at hand.
When it comes to impaired function of chemosensors, 
most scientific publications that report quantitative objec-
tive data focus on olfaction. Publications that focus on 
subjective measures, as is very common during this pan-
demic, cannot—by nature—clearly distinguish between 
olfaction and taste. There are few studies that actually 
tried to measure taste by psychophysical examinations 
[15, 16]. Both studies found an impairment of gustatory 
function during acute infection, that, albeit not statisti-
cally significantly, recovered after infection. It has been 
suggested that this impairment may actually be caused by 
a missing central nervous interaction of taste and smell 
[17]. In respect to taste the dataset at hand is in line with 
the literature available on this topic.
Moreover, there is—to this date—very little data available 
on the course of chemosensory dysfunction in SARS-CoV-2 
infection. It has been reported that approximately two thirds 
of cases with objective hyposmia resolve within 4 weeks 
after infection [6, 18]. The only study that has examined 
the medium-term outcomes of chemosensory function after 
SARS-CoV-2 infection was conducted by Niklassen et al. 
[15] who reported that 27% of patients showed persisting 
hyposmia more than 4 weeks after the infection. These find-
ings are in line with the results reported in the study at hand. 
D’Ascanio and colleagues reported similarly that the major-
ity of patients with subjective impairment of chemosensory 
function recover within 30 days, which again is in line with 
the results presented in the study at hand [18]. Interestingly, 
the patients that had not recovered at the 8-week follow-up 
only rarely recovered until the 6-months follow-up. Bearing 
this in mind, we believe that there are two distinct courses 
of hyposmia in SARS-CoV-2 Infection: The majority (about 
¾) of patients that suffer from subjectively impaired che-
mosensory function recover within the course of 4 weeks 
spontaneously and need no subsequent treatment. However, 
if chemosensory impairment lasts longer than this, a longer 
lasting impairment seems probable. Unfortunately, the data-
set at hand suggests there is no way of determining who 
is to suffer from longer lasting impairment upon the onset 
of symptoms. If olfactory dysfunction persists, olfactory 
training has been recommended as the treatment of choice, 
Table 3  Characteristics of patients with subjective hyposmia over time; H + = subjective hyposmia subjective present at examination, H −  = no 
subjective hyposmia present anymore at examination
Values are given as mean ± standard deviation
Baseline April 
2020 (n = 23)
Follow-up 8 weeks Follow-up 6 months
∑ (n = 20) H + (n = 6) H − (n = 14) ∑ (n = 17) H + (n = 5) H − (n = 12)
SNOT-22 24.2 ± 9.8 17.6 ± 7.6 22.8 ± 6.6 15.3 ± 6.8 20.3 ± 7.7 25.4 ± 6.2 18.2 ± 7.3
VAS 7.9 ± 2.2 3.8 ± 2.6 7.2 ± 1.3 2.4 ± 1.3 3.8 ± 2.7 7.6 ± 1.4 2.3 ± 1.1
B-SIT 4.0 ± 1.7 9.0 ± 3.1 5.0 ± 1.4 10.7 ± 1.7 9.4 ± 2.6 6.4 ± 2.3 10.6 ± 1.1
Normosmia 0 (0.0%) 11 (55.0%) 0 (0.0%) 11 (78.6%) 10 (58.8%) 0 (0.0%) 8 (66.7%)
Hyposmia 6 (27.3%) 8 (40.0%) 5 (83.3%) 3 (21.4%) 6 (35.3%) 4 (80.0%) 4 (33.3%)
Anosmia 16 (72.7%) 1 (5.0%) 1 (16.7%) 0 (0.0%) 1 (5.9%) 1 (20.0%) 0 (0.0%)
Taste strips 2.6 ± 1.3 3.6 ± 0.8 3.7 ± 0.5 3.6 ± 0.9 3.7 ± 0.5 3.2 ± 0.4 3.9 ± 0.3
Normogeusia 10 (45.5%) 18 (90.0%) 6 (100.0%) 12 (85.7%) 17 (100.0%) 4 (100.0%) 12 (100.0%)
Hypogeusia 11 (50.0%) 2 (10.0%) 0 (0.0%) 2 (14.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Ageusia 1 (4.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
 European Archives of Oto-Rhino-Laryngology
1 3
potentially with intranasal sodium citrate or vitamin A [19]. 
Particularly olfactory training has been shown to be very 
effective in post-inflammatory hyposmia, [20, 21] as is the 
case in hyposmia after SARS-CoV-2 infection.
It has long been established in scientific literature that in 
respect to chemosensory function, subjective measures are 
not reliable [22, 23]. However, the dataset at hand provided 
evidence that in (and even after) SARS-CoV-2 Infection, 
there may be some merit to the subjective assessment of 
chemosensory function: There is a considerable proportion 
of patients—both in the control groups and in the follow-
ups—that claim to not suffer from impaired chemosensory 
function but still performed poorly in psychophysical exami-
nations. On the other hand, every patient that claimed to 
actually suffer from impaired chemosensory function per-
formed poorly in in the psychophysical examinations. Sub-
sequently, we believe that while a subjectively unimpaired 
chemosensory function is not indicative of no infection with 
SARS-CoV-2, subjectively impaired chemosensory function 
may very well be indicative of an underlying infection.
The SNOT-22 seems—at least in the study at hand—to 
be able to differentiate between patients that have previously 
tested positive for SARS-CoV-2. However, it does not differ-
entiate between patients that are suffering from subjectively 
impaired chemosensory function and those that do not. This 
is probably due to the fact that several items in the SNOT-
22 are questions about general wellbeing. Fittingly, a study 
from the United Arab Emirates found that patients with more 
severe courses of COVID-19 regularly score higher on these 
items [24]. Bearing in mind that the collective at hand con-
sists of patients that were hospitalized, these patients regu-
larly scoring higher in the SNOT-22 seems logical. Conse-
quently, the validity of the SNOT-22 seems to be impaired 
in patients with concomitant COVID-19 disease.
Conclusion
The majority of patients that suffer from subjectively 
impaired chemosensory function during active COVID-19 
infection actually show impaired sense of smell and/or taste 
in psychophysical testing. Patients that do not state to suffer 
from impaired chemosensory function do not necessarily 
show normal results in psychophysical testing. Moreover, 
the majority of patients that do suffer from subjectively 
impaired chemosensory function recover within 4 weeks 
after the onset of symptoms. However, those patients that 
do not recover within those 4 weeks tend to suffer from these 
symptoms even 6 months after the infection and exhibit fit-
tingly impaired psychophysical test results. These patients 
should be informed about olfactory training and potential 
additional treatments such as sodium citrate and intranasal 
vitamin a.
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